Pfiz­er-backed UK biotech rais­es £25M to ad­vance mi­tophagy pipeline

Mis­sion Ther­a­peu­tics has se­cured £25.2 mil­lion ($32.2 mil­lion) in a Se­ries D raise to ex­tend its run­way through 2026 and sup­port the de­vel­op­ment of its mi­to­chon­dria-tar­get­ing drugs.

The ven­ture arms of Pfiz­er and Roche co-led the raise along­side oth­er ex­ist­ing in­vestors Sofinno­va Part­ners, SR One, IP Group and Roset­ta Cap­i­tal, ac­cord­ing to a com­pa­ny re­lease. The round brings Mis­sion’s to­tal raised to date to £117 mil­lion ($149.8 mil­lion), a com­pa­ny spokesper­son told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER